Primed for
breakthrough

We have cultivated a rapidly growing pipeline, with each molecule offering specific and distinct benefits that can be collectively used to cover a range of chronic inflammatory diseases. Our portfolio of differentiated candidates delivers advances in potency, tissue/brain penetration and chemical structural diversity.

Program
Program
Discovery
Discovery
IND-enabling
IND-enabling
Phase 1
P1
Phase 2
P2
NT-0796
Our lead molecule derived from our proprietary chemistry that is unlike any other NLRP3 inflammasome inhibitor in the space. NT-0796 is designed to deliver an intracellular payload directly to the specific immune cell types that drive inflammatory diseases, with potential applications in peripheral and neuroinflammatory diseases.
NT-0249
NT-0249 is a peripherally-restricted NLRP3 inflammasome inhibitor with excellent potency and optimized development characteristics, allowing us to develop a low-dose therapy with the potential to address chronic inflammatory diseases of the body.
Neuro Development Candidate
This CNS-penetrant compound is uniquely designed from a novel chemotype as a fully brain-penetrant NLRP3 inflammasome inhibitor, with the potential to treat a broad range of neuroinflammatory diseases.
Additional Peripheral/
Neuro Development Candidates
3D render of human body with orange dots pointing to major organs and related disorders associated with NLRP3 inflammasome activation.
3D render of human body with orange dots pointing to major organs and related disorders associated with NLRP3 inflammasome activation.
headshot of Adam Keeney, PhD, President and CEO of NodThera.
Adam Keeney, PhD
Chief Executive Officer
At NodThera, we have the opportunity to deliver on the potential of the NLRP3 inflammasome to change the lives of people impacted by inflammatory disease worldwide
Adam Keeney, PhD
Chief Executive Officer